Daleen Thomas

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

Petros Grivas, Yohann Loriot, Rafael Morales‐Barrera et al. · BMC Cancer · 2021 · 57 citations · Full text

Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial.

Petros Grivas, Yohann Loriot, Susan Feyerabend et al. · Journal of Clinical Oncology · 2020 · 28 citations

Unknown Hrd Status, Urology, Metastatic Urothelial Carcinoma +14

Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer

H. T. See, Daleen Thomas, Carlos Bueso-Ramos et al. · International Journal of Gynecological Cancer · 2006 · 20 citations

Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial

Amit M. Oza, Alla Lisyanskaya, Alexander N. Fedenko et al. · The Lancet Oncology · 2025 · 15 citations

1Rucaparib versus chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: efficacy and safety from ARIEL4, a randomized phase III study

Rebecca Kristeleit, Alla Lisyanskaya, Alexander N. Fedenko et al. · Gynecologic Oncology · 2021 · 13 citations